Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Expert Opin Biol Ther. 2012 Nov 29;13(2):283–294. doi: 10.1517/14712598.2012.745508

Table 1.

Phase II trials of bevacizumab

GOG Cannistra et al. McGonigle et al. Carmen et al. Garcia et al.
Setting/design Recurrent platinum- sensitive/resistant Recurrent platinum- resistant Recurrent platinum- resistant Recurrent platinum- sensitive Recurrent platinum- sensitive/resistant
Bev dosage 15mg/kg/q3w 15mg/kg/q3w 10mg/kg/q2w 10mg/kg/q2w 10mg/kg**
Treatment Monotherapy Monotherapy Combination with TOP Combination with PLD and CBDCA Combination with cyclophosphamide
Treatment cycle (days) 21 21 28 28 28
Number of patients 62 44 40 54 70
Efficacy
 ORR 21.0% 15.9% 25.0% 72.2% 24%
 CR 2 (3%) 0 0 8 (15%) 0
 PR 11 (18%) 7 (15.9%) 10 (25%) 31 (57%) 17 (24%)
 SD 32 (52%) 27 (25%) 14 (35%) 11 (20%) 44 (63%)
 Median PFS (range) (months) 4.7 (2.7–12.9*) 4.4 (3.1–5.5) 7.8 (3.0–9.4) 13.9 (11.4– 16.0) 7.2 (5.3–8.7)
 Median OS (range) (months) 16.9 (9.1–32.4*) 10.7 16.6 (12.8– 22.9) N/A 16.9 (11.4–25.2)
Adverse events (selected)
 Hypertension (>grade3) 6 (9.7%) 4 (9.1%) 8 (20%) 6 (11.1%) 11 (15%)
 GI perforation 0 5 (11%) 0 1 (1.9%) 3 (4%)
 Proteinuria (>grade3) 1 (1.6%) 0 1 (3%) 6 (11.1%) 3 (4%)
 VTE 2 (3.2%) 1 (2.3%) 1 (3%) 2 (3.7%) 3 (4%)

GOG, gynecologic oncology group; Bev, bevacizumab; TOP, topotecan; PLD, pegylated liposomal doxorubicin; CBDCA, carboplatin; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival; GI, gastrointestinal; VTE, venous thromboembolism

*

first and third quartiles

**

every week for first 3 weeks of treatment followed by administration every 2 weeks